Prelude Therapeutics Incorporated (NASDAQ: PRLD) was upgraded by analysts at HC Wainwright from a "hold" rating to a "strong-buy" rating.
Prelude Therapeutics Incorporated (NASDAQ: PRLD) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $7.00 price target on the stock.
Prelude Therapeutics Incorporated (NASDAQ: PRLD) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial
Prelude Therapeutics Incorporated (NASDAQ: PRLD) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.